Nobilis Therapeutics
Clinical-stage biotechnology company developing inhalation-based therapeutics that use controlled self-administration of inert gas mixtures and a portable inhalation device to treat psychiatric and neurodegenerative disorders. The company is advancing programs into human clinical trials and maintains an intellectual property and grant-funded research portfolio.
Industries
Nr. of Employees
small (1-50)
Nobilis Therapeutics
Patents
Portable devices for administration of therapeutic gas mixtures and methods of use
US-11103671-B2
View Details
Portable devices for administration of therapeutic gas mixtures and methods of use
US-11103671-B2
View DetailsProducts
Inhalation-based therapeutic development programs
Therapeutic development programs using controlled inhalation of inert gas mixtures targeting psychiatric and neurodegenerative conditions.
Portable inhalation delivery device
Portable device intended to enable controlled self-administration of therapeutic gas mixtures with reproducible dosing and exposure.
Inhalation-based therapeutic development programs
Therapeutic development programs using controlled inhalation of inert gas mixtures targeting psychiatric and neurodegenerative conditions.
Portable inhalation delivery device
Portable device intended to enable controlled self-administration of therapeutic gas mixtures with reproducible dosing and exposure.
Expertise Areas
- Inhalation therapeutics development
- Clinical trial design and execution for central nervous system indications
- Portable medical device development
- Gas formulation and standardization
Key Technologies
- Inhalation delivery systems
- Controlled gas mixture formulation
- Portable medical device engineering
- Clinical trial design and execution
News & Updates
Company selected to present at the CONNECTpreneur investor event.
Company participation in a digital partnering event for business development.
Company's treatment approach discussed favorably in a systematic review article on experimental drugs for panic disorder.
Validation formalities completed for a European patent licensed from another institution in multiple European countries.
Award received to study an inhaler-based approach for rapid reduction of opioid withdrawal symptoms.
Company selected to present at the CONNECTpreneur investor event.
Company participation in a digital partnering event for business development.
Company's treatment approach discussed favorably in a systematic review article on experimental drugs for panic disorder.
Validation formalities completed for a European patent licensed from another institution in multiple European countries.
Award received to study an inhaler-based approach for rapid reduction of opioid withdrawal symptoms.